Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kümpfel, T.
Right arrow Articles by Trenkwalder, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kümpfel, T.
Right arrow Articles by Trenkwalder, C.
Neurology 2000;55:1231-1233
© 2000 American Academy of Neurology
Brief Communications

Acute effects of interferon beta-1a on plasma cytokine levels in patients with MS

T. Kümpfel, MD, F. Then Bergh, MD, T. Pollmächer, MD, F. Holsboer, MD, PhD and C. Trenkwalder, MD

From the Max Planck Institute of Psychiatry, Section of Neurology, Munich, Germany.

Address correspondence and reprint requests to Dr. T. Kümpfel, Max Planck Institute of Psychiatry, Kraepelinstr. 10, D-80804 Munich, Germany; e-mail: kuempfel{at}mpipsykl.mpg.de

The acute effects of a i.m. injection of interferon beta-1a on the secretion of the cytokines interleukin-6, tumor necrosis factor-{alpha}, soluble tumor necrosis factor receptor I, and interleukin-1 receptor antagonist and its relation to peripheral concentrations of adrenocorticotropic hormone (ACTH) and cortisol in patients with MS were investigated, as well as the influence of cotreatment with indomethacin on these parameters. After interferon beta injection we found an acute rise in plasma cytokine levels and an increase in plasma hormone concentrations, both of which were modulated by indomethacin comedication.




This article has been cited by other articles:


Home page
 Mult SclerHome page
A. Ledinek, S. Jazbec, I Drinovec, and U Rot
Pulmonary arterial hypertension associated with interferon beta treatment for multiple sclerosis: a case report
Multiple Sclerosis, July 1, 2009; 15(7): 885 - 886.
[Abstract] [PDF]

Home page
 Mult SclerHome page
T. Kumpfel, M. Schwan, Th. Pollmacher, A. Yassouridis, M. Uhr, C. Trenkwalder, and F. Weber
Time of interferon-{beta} 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients
Multiple Sclerosis, November 1, 2007; 13(9): 1138 - 1145.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L L. Mantia, D D'Amico, A Rigamonti, N Mascoli, G Bussone, and C Milanese
Interferon treatment may trigger primary headaches in multiple sclerosis patients
Multiple Sclerosis, August 1, 2006; 12(4): 476 - 480.
[Abstract] [PDF]

Home page
 NeurologyHome page
W. Pollmann, L. -P. Erasmus, W. Feneberg, F. T. Bergh, and A. Straube
Interferon beta but not glatiramer acetate therapy aggravates headaches in MS
Neurology, August 27, 2002; 59(4): 636 - 639.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by AAN Enterprises, Inc.